Alexion, AstraZeneca Rare Disease

Alexion, AstraZeneca Rare Disease is the rare disease group within AstraZeneca, formed following the 2021 acquisition of Alexion Pharmaceuticals.

With nearly 30 years of rare disease heritage, the division focuses on novel molecules targeting the complement cascade across haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology.

Its portfolio spans established rare disease medicines and a pipeline of next-generation complement inhibitors serving patients in more than 50 countries.